1398044-76-2

Upstream product

• 1398044-67-1 methyl 2-azido-3-O-benzyl-2-deoxy-1-thio-β-D-glucopyranoside 
• 1398044-68-2 methyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-1-thio-β-D-glucopyranoside 
• 100-39-0 benzyl bromide 
• 1398044-69-3 methyl 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-4-O-(9-fluorenylmethyloxycarbonyl)-1-thio-β-D-glucopyranoside 
• 1398044-75-1 4-methoxyphenyl 2-O-benzoyl-3-O-benzyl-6-O-chloroacetyl-β-D-glucopyranoside 
• 428865-77-4 4-methoxyphenyl 2-O-benzyol-3-O-benzyl-β-D-glucopyranoside 
• 282526-05-0 methyl 2-azido-4,6-di-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside 

Downstream Products

• 1398047-52-3 C₅₂H₅₀ClN₃O₁₅ 
• 1398044-81-9 C₅₂H₅₀ClN₃O₁₅ 
• 1398044-90-0 C₄₄H₄₆ClN₃O₁₄ 
• 1398047-58-9 C₅₄H₅₀Cl₄N₄O₁₅ 
• 1398044-85-3 C₅₄H₅₀Cl₄N₄O₁₅ 

Relevant academic research and scientific papers

Using automated glycan assembly (AGA) for the practical synthesis of heparan sulfate oligosaccharide precursors

Herein we report synthesis of complex heparan sulfate oligosaccharide precursors by automated glycan assembly using disaccharide donor building blocks. Rapid access to a hexasaccharide was achieved through iterative solid phase glycosylations on a photolabile resin using Glyconeer, an automated oligosaccharide synthesiser, followed by photochemical cleavage and glycan purification using simple flash column chromatography.

Oligosaccharide compounds

The invention relates generally to oligosaccharide compounds and the use of these compounds as pharmaceuticals for treating diseases or conditions in which it is desirable to inhibit β-secretase.

Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of β-secretase: Potential therapeutics for Alzheimer's disease

Heparan sulfates (HS) are a class of sulfated polysaccharides that function as dynamic biological regulators of the functions of diverse proteins. The structural basis of these interactions, however, remains elusive, and chemical synthesis of defined structures represents a challenging but powerful approach for unravelling the structure-activity relationships of their complex sulfation patterns. HS has been shown to function as an inhibitor of the β-site cleaving enzyme β-secretase (BACE1), a protease responsible for generating the toxic Aβ peptides that accumulate in Alzheimer's disease (AD), with 6-O-sulfation identified as a key requirement. Here, we demonstrate a novel generic synthetic approach to HS oligosaccharides applied to production of a library of 16 hexa- to dodecasaccharides targeted at BACE1 inhibition. Screening of this library provided new insights into structure-activity relationships for optimal BACE1 inhibition, and yielded a number of potent non-anticoagulant BACE1 inhibitors with potential for development as leads for treatment of AD through lowering of Aβ peptide levels. Copyright